Does the media prefer PLYX or FENC?

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 3 mentions for Polaryx Therapeutics. Adherex Technologies' average media sentiment score of 0.66 beat Polaryx Therapeutics' score of 0.25 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ENTA or PLYX?

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 1.60 beat Polaryx Therapeutics' score of 0.25 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PLYX or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 10 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.25 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PLYX or PALI more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Palisade Bio N/A -33.47% -31.79%

Does the media refer more to PLYX or PALI?

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 3 articles in the media. Palisade Bio's average media sentiment score of 1.31 beat Polaryx Therapeutics' score of 0.25 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PLYX or IKT more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media favor PLYX or IKT?

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 3 mentions for Polaryx Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Polaryx Therapeutics' score of 0.25 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Polaryx Therapeutics (PLYX) Competitors

$1.99 -0.05 (-2.45%)

As of 09/3/2026 04:00 PM Eastern

Compare

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

Should you buy Polaryx Therapeutics stock or one of its competitors? Polaryx Therapeutics's main competitors and comparable companies include Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), Eyepoint Pharmaceuticals (EYPT), Palisade Bio (PALI), and Inhibikase Therapeutics (IKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polaryx Therapeutics compare to Adherex Technologies?

Polaryx Therapeutics (NASDAQ:PLYX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Polaryx Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 285.26%. Adherex Technologies has a consensus price target of $17.00, suggesting a potential upside of 35.46%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Polaryx Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

55.5% of Adherex Technologies shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Polaryx Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Polaryx Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Adherex Technologies	-6.09%	-5.71%	-2.37%

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 3 mentions for Polaryx Therapeutics. Adherex Technologies' average media sentiment score of 0.66 beat Polaryx Therapeutics' score of 0.25 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Polaryx Therapeutics has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A

Summary

Polaryx Therapeutics beats Adherex Technologies on 10 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 1.60 beat Polaryx Therapeutics' score of 0.25 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals presently has a consensus price target of $19.50, indicating a potential upside of 39.09%. Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 285.26%. Given Polaryx Therapeutics' higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	6.26	-$81.89M	-$2.41	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Polaryx Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Polaryx Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Polaryx Therapeutics (NASDAQ:PLYX) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Polaryx Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 285.26%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, indicating a potential upside of 462.36%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

In the previous week, Eyepoint Pharmaceuticals had 10 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.25 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polaryx Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Polaryx Therapeutics' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Polaryx Therapeutics has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A

Summary

Polaryx Therapeutics beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Palisade Bio?

Polaryx Therapeutics (NASDAQ:PLYX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Polaryx Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Palisade Bio	N/A	-33.47%	-31.79%

11.8% of Palisade Bio shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Polaryx Therapeutics has higher earnings, but lower revenue than Palisade Bio. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A

Polaryx Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 285.26%. Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 340.10%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 3 articles in the media. Palisade Bio's average media sentiment score of 1.31 beat Polaryx Therapeutics' score of 0.25 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palisade Bio beats Polaryx Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Polaryx Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Polaryx Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 285.26%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 114.29%. Given Polaryx Therapeutics' higher possible upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Polaryx Therapeutics has higher earnings, but lower revenue than Inhibikase Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Inhibikase Therapeutics	$260K	1,352.46	-$48.26M	-$0.43	N/A

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 3 mentions for Polaryx Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Polaryx Therapeutics' score of 0.25 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inhibikase Therapeutics beats Polaryx Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$101.69M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-24.88	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	9.05	12.33	12.89	6.14
Net Income	-$8.98M	$2.82B	$3.47B	$349.01M
7 Day Performance	-3.40%	2.59%	0.60%	-0.27%
1 Month Performance	-10.76%	6.95%	5.73%	0.68%
1 Year Performance	N/A	9.45%	25.35%	14.84%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	2.8062 of 5 stars	$1.99 -2.5%	$7.67 +285.3%	N/A	$101.69M	N/A	N/A	11
FENC Adherex Technologies	4.4017 of 5 stars	$12.27 +4.2%	$17.00 +38.5%	+41.6%	$412.64M	$44.64M	N/A	10	Positive News
ENTA Enanta Pharmaceuticals	1.9035 of 5 stars	$13.60 -1.4%	$19.50 +43.4%	+59.0%	$401.93M	$65.26M	N/A	160	Positive News
EYPT Eyepoint Pharmaceuticals	2.499 of 5 stars	$4.48 -3.2%	$28.11 +527.5%	-61.9%	$399.16M	$31.37M	N/A	120	Analyst Upgrade
PALI Palisade Bio	2.7361 of 5 stars	$2.00 -5.2%	$9.00 +350.0%	+215.4%	$367.71M	$250K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

How does Polaryx Therapeutics compare to Adherex Technologies?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Palisade Bio?

Summary

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

How does Polaryx Therapeutics compare to Adherex Technologies?

Do analysts prefer PLYX or FENC?

Do insiders & institutionals hold more shares of PLYX or FENC?

Is PLYX or FENC more profitable?

Does the media prefer PLYX or FENC?

Which has better valuation & earnings, PLYX or FENC?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Does the media favor ENTA or PLYX?

Do analysts recommend ENTA or PLYX?

Which has stronger valuation and earnings, ENTA or PLYX?

Do insiders and institutionals have more ownership in ENTA or PLYX?

Is ENTA or PLYX more profitable?

Summary

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Do insiders & institutionals believe in PLYX or EYPT?

Do analysts recommend PLYX or EYPT?

Does the media prefer PLYX or EYPT?

Is PLYX or EYPT more profitable?

Which has preferable valuation and earnings, PLYX or EYPT?

Summary

How does Polaryx Therapeutics compare to Palisade Bio?

Is PLYX or PALI more profitable?

Do insiders and institutionals believe in PLYX or PALI?

Which has preferable earnings and valuation, PLYX or PALI?

Do analysts rate PLYX or PALI?

Does the media refer more to PLYX or PALI?

Summary

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Is PLYX or IKT more profitable?

Do institutionals & insiders believe in PLYX or IKT?

Do analysts recommend PLYX or IKT?

Which has stronger valuation & earnings, PLYX or IKT?

Does the media favor PLYX or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools